The ONO study is testing a new oral medication, ONO-2020, for people with mild to moderate Alzheimer’s disease. The goal is to see if the medication can slow the progression of symptoms by targeting gene expression.
Who can join?
You may be eligible if you:
-
Are between 55 and 85 years old
-
Have been diagnosed with mild to moderate Alzheimer’s disease
-
Have had a brain MRI or CT scan in the past year
-
Have a reliable study partner who can attend visits and help with pill management
-
Have not received treatment with anti-amyloid therapies
What does participation involve?
-
Screening period: Up to 6 weeks to confirm eligibility
-
Study period: 26 weeks of daily study treatment (ONO-2020 or placebo)
-
Follow-up: 4 weeks of monitoring after treatment ends
Study design
This is a Phase 2, double-blind, placebo-controlled study. Participants are randomly assigned to one of three groups:
-
20 mg of ONO-2020 daily
-
60 mg of ONO-2020 daily
-
Placebo
Click here for a printable flier about this study
Interested or have questions?
Contact Ashal Malik and Melissa Kelley at ONOstudy@pennmedicine.upenn.edu